Variant recurrent risk among stroke patients with differentCYP2C19phenotypes and treated with clopidogrel
about
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) studyPlatelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature.Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population.Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
P2860
Variant recurrent risk among stroke patients with differentCYP2C19phenotypes and treated with clopidogrel
description
im September 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2014
@uk
name
Variant recurrent risk among s ...... s and treated with clopidogrel
@en
Variant recurrent risk among s ...... s and treated with clopidogrel
@nl
type
label
Variant recurrent risk among s ...... s and treated with clopidogrel
@en
Variant recurrent risk among s ...... s and treated with clopidogrel
@nl
prefLabel
Variant recurrent risk among s ...... s and treated with clopidogrel
@en
Variant recurrent risk among s ...... s and treated with clopidogrel
@nl
P2093
P2860
P1433
P1476
Variant recurrent risk among s ...... s and treated with clopidogrel
@en
P2093
Junrong Li
Liping Cao
Qiankun Cai
Ruibing Guo
Wenhua Liu
Wenshan Sun
Wusheng Zhu
Xiaomeng Wang
P2860
P304
P356
10.3109/09537104.2014.953044
P50
P577
2014-09-10T00:00:00Z